P2Y(2) receptor agonists: a new class of medication targeted at improved mucociliary clearance.
Chronic bronchitis is in part characterized by mucus hypersecretion and the inability to clear airways of mucus. Despite years of research in this area, to date there are no pharmacologic therapies available to enhance or promote mucociliary clearance. P2Y(2) receptor agonists are a new class of mucoactive compounds that are currently under development for this purpose. This article will review the pharmacology of P2Y(2) receptor agonists, review the clinical studies performed to date, and highlight the challenges inherent in the development of therapies with these pharmacologic properties.
Kellerman
Donald J
DJ
Inspire Pharmaceuticals, 4222 Emperor Boulevard, Suite 470, Durham, NC 27703, USA. dk@inspirepharm.com
D000818:Animals; D018927:Anti-Asthmatic Agents / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D029481:Bronchitis, Chronic / Q000188:drug therapy*; D003550:Cystic Fibrosis / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D006801:Humans; D009079:Mucociliary Clearance / Q000187:drug effects*; D009883:Ophthalmic Solutions; D011122:Polyphosphates; D058910:Purinergic P2 Receptor Agonists; D058473:Receptors, Purinergic P2Y2; D014500:Uracil Nucleotides; D014544:Uridine Triphosphate / Q000502:physiology
D018927:Anti-Asthmatic Agents; D009883:Ophthalmic Solutions; C546385:P2RY2 protein, human; D011122:Polyphosphates; D058910:Purinergic P2 Receptor Agonists; D058473:Receptors, Purinergic P2Y2; D014500:Uracil Nucleotides; C403315:diquafosol; D014544:Uridine Triphosphate